Medical/Pharmaceuticals

Complete Genomics Partners with Integrated DNA Technologies to Establish New Ecosystem of NGS Products

SAN JOSE, California, Oct. 18, 2023 /PRNewswire/ -- Complete Genomics, Inc., a pioneering genomic sequencing company, today announced its partnership with Integrated DNA Technologies (IDT), a global genomics solutions provider, to develop an ecosystem of advanced com...

2023-10-18 20:00 1543

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study

BRENTWOOD, Tenn., Oct. 18, 2023 /PRNewswire/ -- Currax Pharmaceuticals LLC  ("Currax") today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA). This study evaluated the cardiovascular safety of CONTRAVE®/MYSIMBA®, a weight management drug. The real-world study compare...

2023-10-18 20:00 1732

Seegene Reinforces Commitment to Strong ESG Management with 100% Recyclable, Styrofoam-Free Shipping Boxes

* 100% recyclable package made with eco-friendly and FSC-certified materials to proactively meet evolving global environmental regulations * Patent design provides a 30% increase in load capacity and an up to 52% reduction in transportation costs * This initiative is part of Seegene's effort...

2023-10-18 19:00 2107

Telix reports fourth consecutive quarter of positive operating cash flow

MELBOURNE, Australia, Oct. 18, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended30 September 2023 (Q3 2023). All figures are in AUD$ unless otherwise s...

2023-10-18 15:42 1539

Yuyu Pharma to attend 'CPHI Worldwide 2023'

SEOUL, South Korea, Oct. 18, 2023 /PRNewswire/ -- Yuyu Pharma will be attending CPHI Worldwide inBarcelona, Spain from October 24th to October 26th. Yuyu Pharma to attend ‘CPHI Worldwide 2023’ The Yuyu Business Development team will be able to meet...

2023-10-18 15:00 2322

Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures

* These results are from Japan's first domestic Phase 3 clinical trial of an intranasally administered antiepileptic drug for Japanese patients aged 6 to 17 for the treatment of status epilepticus or epileptic seizures that may lead to status epilepticus. * The primary efficacy endpoint was...

2023-10-18 14:00 1441

WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong

* Hong Kong Science and Technology Parks Corporation (HKSTPC) and WuXi XDC signed a cooperation framework agreement to jointly promote the establishment of a contract research, development and manufacturing organization(CRDMO) value chain inHong Kong. * HKSTP Park companies will leverage WuXi...

2023-10-18 11:00 1527

First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

SUZHOU, China and ROCKVILLE, Md., Oct. 17, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the registrational Phase III study (HQP1351AG...

2023-10-18 10:11 1474

Bridging the Healthcare Gap in Thailand and Beyond with the Belt and Road Initiative

BANGKOK, Oct. 18, 2023 /PRNewswire/ -- "I have a dream that everyone should have the ability to access medical care equally," says Oraphan Wanacharoen (Ice), BGI Genomics Field Application Scientist. "It's very challenging to achieve such a goal inThailand. With the advanced technology of the com...

2023-10-18 08:21 2254

New Results From HEALEY ALS Platform Trial Show Promise for Treating ALS

MONTREAL, Oct. 18, 2023 /PRNewswire/ -- One of the central challenges of Amyotrophic Lateral Sclerosis ALS research is finding ways to slow the progression of the relentlessly degenerative brain disease. Recently, based on results of theHEALEY ALS Platform Trial, two experimental medications plan...

2023-10-18 03:04 1594

Neurologist Anthony Lang Presents Groundbreaking News on Parkinson's Disease at World Congress of Neurology 2023

MONTREAL, Oct. 18, 2023 /PRNewswire/ -- During a plenary lecture at the 26th World Congress of Neurology, Dr. Anthony Lang, professor of neurology and Jack Clark Chair for Parkinson's Disease Research,University of Toronto, revealed a groundbreaking new model for identifying and studying Parkinso...

2023-10-18 02:59 1590

Bio4t2 announces trial evaluating repeat infusions of CAR-T targeting solid tumors without lymphodepletion

SAN DIEGO and SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Bio4t2® received regulatory approvals to repeatedly administer patients with T cells engineered to express a chimeric antigen receptor (CAR) targeting BT-001, an antigen on solid tumors identified using the PrismCore™ platform. The CAR-T, term...

2023-10-17 23:17 1925

Ubie's new Generative AI feature for doctors effortlessly summarizes patient findings and streamlines medical record documentation with a 90% User Satisfaction rate.

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Ubie , Inc. (Headquartered in Chuo-ku,Tokyo, Co-Representative Directors: Yoshinori Abe & Kota Kubo, referred to as 'Ubie') released a new feature utilizing generative AI (LLM: Large Language Model) for doctors to generate AI...

2023-10-17 23:00 1910

Congratulations to Sanyou Bio for achieving ISO9001 & IPMS certifications

SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd is pleased to announce inOctober 2023, we have obtained ISO 9001 and IPMS certifications. These certifications emphasize Sanyou's commitment to consistency, reliability, and accountability in our innovative biopharmaceuti...

2023-10-17 21:00 1502

Global Healthcare Startup Sky Labs Attracts Investments Totaling KRW 20.7 Billion in a Series C Round

- Major investors include Korea Development Bank (KDB), K2 Investment Partners, DEVSISTERS VENTURES, SJG Partners, and OPENWATER INVESTMENT - Distribution of 'CART BP,' a ring-type cuffless blood pressure monitor that enables continuous blood pressure measurement and monitoring 24/7, will be ful...

2023-10-17 20:00 1634

SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement

ZUG, Switzerland, Oct. 17, 2023 /PRNewswire/ -- SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedica...

2023-10-17 17:00 3674

Docquity pioneers the first regional job platform focused on Southeast Asia's healthcare professionals

* Docquity Jobs enables healthcare organizations to access the region's largest database of medical talent across different specialities * In just one year, the job portal has expanded to four countries with around 400 employers on board * Docquity Jobs has seen a 30% month-on-month growth...

2023-10-17 10:00 3046

CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation inChina,  committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announ...

2023-10-17 08:00 10095

World Health Organization Presents Global Action Plan for Neurological Disorders at World Congress of Neurology

MONTREAL, Oct. 16, 2023 /PRNewswire/ -- The World Health Organization (WHO) revealed its new Intersectoral Global Action Plan (IGAP), a critical blueprint for combating neurological conditions that calls for urgent action from governments and health care organizations around the world. IGAP outli...

2023-10-16 22:50 1610

Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology(ESMO)

SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib(ABSK011)and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with...

2023-10-16 21:50 1751
1 ... 137138139140141142143 ... 611